Bahman Abedi Kiasari

Dr. Bahman Abedi Kiasari

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MSMohamed J. Saadh
Mohamed J. Saadh
MMMaria V. Mikhailova
Maria V. Mikhailova
SRSoheil Rasoolzadegan
Soheil Rasoolzadegan
MFMojgan Falaki
Mojgan Falaki
RARoozbeh Akhavanfar
Roozbeh Akhavanfar
BKBahman Abedi Kiasari
Bahman Abedi Kiasari
Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes. MSCs alleviate dysregulated inflammatory responses through the secretion of a myriad of anti-inflammatory mediators, such as interleukin 10 (IL-10), transforming growth factor-β (TGFβ), prostaglandin E2 (PGE2), tumor necrosis factor-stimulated gene-6 (TSG-6), etc. Indeed, MSC treatment of IBD is largely carried out through local microcirculation construction, colonization and repair, and immunomodulation, thus alleviating diseases severity. The clinical therapeutic efficacy relies on to the marked secretion of various secretory molecules from viable MSCs via paracrine mechanisms that are required for gut immuno-microbiota regulation and the proliferation and differentiation of surrounding cells like intestinal epithelial cells (IECs) and intestinal stem cells (ISCs). For example, MSCs can induce IECs proliferation and upregulate the expression of tight junction (TJs)-associated protein, ensuring intestinal barrier integrity. Concerning the encouraging results derived from animal studies, various clinical trials are conducted or ongoing to address the safety and efficacy of MSCs administration in IBD patients. Although the safety and short-term efficacy of MSCs administration have been evinced, the long-term efficacy of MSCs transplantation has not yet been verified. Herein, we have emphasized the illumination of the therapeutic capacity of MSCs therapy, including naïve MSCs, preconditioned MSCs, and also MSCs-derived exosomes, to alleviate IBD severity in experimental models. Also, a brief overview of published clinical trials in IBD patients has been delivered.

1 September 2008 in Journal of Clinical Virology
Verified
Journal Article
Closed access
BKBahman Abedi Kiasari
Bahman Abedi Kiasari
PVP.J. Vallely
P.J. Vallely
CCC.E. Corless
C.E. Corless
MAM. Al-Hammadi
M. Al-Hammadi
PKP.E. Klapper
P.E. Klapper

11 March 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SBShunshun Bao
Shunshun Bao
MDMohammad Darvishi
Mohammad Darvishi
Ali Hassan AminAli Hassan Amin
Ali Hassan Amin
MAMaysoon T. Al-Haideri
Maysoon T. Al-Haideri
IPIndrajit Patra
Indrajit Patra
RAReza Akhavan-Sigari
Reza Akhavan-Sigari

17 February 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
AHAliakbar Hasankhani
Aliakbar Hasankhani
ABAbolfazl Bahrami
Abolfazl Bahrami
BTBahareh Tavakoli-Far
Bahareh Tavakoli-Far
SISetare Iranshahi
Setare Iranshahi
FGFarnaz Ghaemi
Farnaz Ghaemi
ASAlireza Mohammadzadeh Shabestari
Alireza Mohammadzadeh Shabestari
Coronavirus disease 2019 (COVID-19) is a severe respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the lower and upper respiratory tract in humans. SARS-CoV-2 infection is associated with the induction of a cascade of uncontrolled inflammatory responses in the host, ultimately leading to hyperinflammation or cytokine storm. Indeed, cytokine storm is a hallmark of SARS-CoV-2 immunopathogenesis, directly related to the severity of the disease and mortality in COVID-19 patients. Considering the lack of any definitive treatment for COVID-19, targeting key inflammatory factors to regulate the inflammatory response in COVID-19 patients could be a fundamental step to developing effective therapeutic strategies against SARS-CoV-2 infection. Currently, in addition to well-defined metabolic actions, especially lipid metabolism and glucose utilization, there is growing evidence of a central role of the ligand-dependent nuclear receptors and peroxisome proliferator-activated receptors (PPARs) including PPARα, PPARβ/δ, and PPARγ in the control of inflammatory signals in various human inflammatory diseases. This makes them attractive targets for developing therapeutic approaches to control/suppress the hyperinflammatory response in patients with severe COVID-19. In this review, we (1) investigate the anti-inflammatory mechanisms mediated by PPARs and their ligands during SARS-CoV-2 infection, and (2) on the basis of the recent literature, highlight the importance of PPAR subtypes for the development of promising therapeutic approaches against the cytokine storm in severe COVID-19 patients.

19 October 2011 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
BKBahman Abedi Kiasari
Bahman Abedi Kiasari
PVPamela J. Vallely
Pamela J. Vallely
PKPaul E. Klapper
Paul E. Klapper
Merkel cell polyomavirus (MCPyV) was identified originally in association with a rare but aggressive skin cancer, Merkel cell carcinoma. The virus has since been found in the respiratory tract of some patients with respiratory disease. However, the role of MCPyV in the causation of respiratory disease has not been established. To determine the prevalence of MCPyV in 305 respiratory samples from immunocompetent and immunocompromised patients and evaluate their contribution to respiratory diseases, specimens were screened for MCPyV using single, multiplex, or real-time PCR; co-infection with other viruses was examined. Of the 305 samples tested, 10 (3.27%) were positive for MCPyV. The virus was found in two groups of patients: in 6 (2%) nasopharyngeal aspirate samples from children aged 26 days to 7 months who were immunocompetent; and in 4 (1.3%) of nasopharyngeal aspirate samples taken from patients aged 41 to 69 years who were severely immunosuppressed from leukemia or transplant therapy. Both groups had upper or lower respiratory tract infection. Co-infections with other viruses were found in 30% of the MCPyV positive samples. The data present a pattern of infection similar to that seen with the polyomaviruses JC and BK in which the virus is acquired during childhood, probably by the respiratory route. The viruses then establish latency and become reactivated in the event of immunosuppression. J. Med. Virol. 83:2220–2224, 2011.

1 November 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
BKBahman Abedi Kiasari
Bahman Abedi Kiasari
AAArash Abbasi
Arash Abbasi
NDNadia Ghasemi Darestani
Nadia Ghasemi Darestani
NANasim Adabi
Nasim Adabi
AMarsalan Moradian
arsalan Moradian
SJSheida Janati
Sheida Janati